Phase III additional clinical study of 111In-pentetreotide (MP-1727): diagnosis of gastrointestinal hormone producing tumors based on the presence of somatostatin receptors.
Phase III additional clinical study of 111In-Pentetreotide (MP-1727): diagnosis of gastrointestinal hormone -producing tumors based on the presence of somatostatin receptors.